Pain News and Research

Latest Pain News and Research

Zyga Technology raises $25 million in Series C financing

Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.

17 May 2012

Dangerous, complex migraines linked to high risk for stroke

Nicole Soriano had headaches before but nothing like the one that struck in the middle of one summer night. A coincidence led nine days later to Cedars-Sinai Medical Center, where a rare type of migraine was diagnosed and treated - but any moment during that time could have been disastrous.

16 May 2012

VATS plays a valuable role in lung cancer screening program

The most recent research released in June's Journal of Thoracic Oncology says video assisted thoracic surgery (VATS) is a valuable tool in managing lesions detected in a lung cancer screening program.

16 May 2012

Researchers map processes that power health benefits of omega-3 fatty acids

For the first time, researchers at the University of California, San Diego have peered inside a living mouse cell and mapped the processes that power the celebrated health benefits of omega-3 fatty acids. More profoundly, they say their findings suggest it may be possible to manipulate these processes to short-circuit inflammation before it begins, or at least help to resolve inflammation before it becomes detrimental.

16 May 2012

Diabetes may affect 53.1M Americans by 2025: Study

The Diabetes 2025 Model for the U.S. projects a continuous and dramatic increase in the diabetes epidemic and makes it possible to estimate the potential effects of society-wide changes in lifestyle and healthcare delivery systems.

16 May 2012

Biomarker test can accurately detect early arthritis symptoms

More than 27 million adults currently suffer from osteoarthritis, which is the most common form of arthritis. In the past, doctors have been unable to diagnose patients with arthritis until they begin to show symptoms, which include joint pain and stiffness. By the time these symptoms are present, it is often too late for preventive and minimally invasive treatment options to be effective. Now, a research team from the University of Missouri's Comparative Orthopaedic Laboratory has found a way to detect and predict arthritis before patients begin suffering from symptoms.

16 May 2012

Avita commences enrollment in ReCell study for hypertrophic dyspigmented scars

Avita Medical Ltd.,the regenerative medicine company, today announced that it has commenced enrolment in the US FDA-approved feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars.

16 May 2012

Medical Marijuana reports net income of $1.21M for first quarter 2012

Medical Marijuana, Inc., one of the medical marijuana (MMJ) industry's premier cannabis and hemp industry innovators, today announced its first quarter earnings. The company earned net income of approximately $1.21 million on gross revenues of $1.79 million for the quarter ended March 31, 2012.

16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

AxioMed’s Freedom Cervical Disc receives CE Mark approval

AxioMed Spine Corporation announces the receipt of CE Mark approval for its Freedom Cervical Disc, an elastomeric total spinal disc replacement device.

16 May 2012

InVivo Therapeutics reports net income of $3,150,000 for first quarter 2012

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported the financial results for the three months ended March 31, 2012 and provided a business update.

15 May 2012

Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Scientists at Weill Cornell Medical College have discovered that the single protein -- alpha 2 delta -- exerts a spigot-like function, controlling the volume of neurotransmitters and other chemicals that flow between the synapses of brain neurons. The study, published online in Nature, shows how brain cells talk to each other through these signals, relaying thoughts, feelings and action, and this powerful molecule plays a crucial role in regulating effective communication.

15 May 2012

Women more likely to have different set of sports injuries than men

With the predominance of male athletes featured on television and covered in the media year-round, most Americans are familiar with some of the most common injuries sustained by men in various sports. As the 2012 Summer Games approaches, female athletes will have additional opportunities to be featured, but are their potential injury risks the same as their male counterparts?

15 May 2012

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Cubist Pharmaceuticals, Inc. today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.

15 May 2012

Five new capabilities added to Aetna Rx Check Program

Aetna today announced that it is adding five new capabilities to Aetna Rx Check, a collection of programs designed to promote safety and prevent the misuse of various prescription drugs such as pain medications and antibiotics.

15 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

OIC introduces Pedicle Screw System

The Orthopaedic Implant Company (OIC) has announced the launch of its Pedicle Screw System. The new product line is used for stabilization and fixation during posterior spinal fusion procedures.

15 May 2012

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

BioAlliance Pharma commences Livatag phase III trial in hepatocellular carcinoma

BioAlliance Pharma SA, a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag(doxorubicin Transdrug), as scheduled in the advancement calendar of the project.

15 May 2012

National program in Botswana focuses on increasing male circumcision rate

Botswana, Lesotho, Swaziland, Zambia, and Zimbabwe all have launched national campaigns urging men to undergo circumcision to help reduce their risk of contracting or transmitting HIV infection, but "all the countries are lagging far behind their targets," Agence France-Presse reports in an article focusing on efforts in Botswana.

14 May 2012